terfenadine has been researched along with fluoxetine in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (24.00) | 18.2507 |
| 2000's | 6 (24.00) | 29.6817 |
| 2010's | 11 (44.00) | 24.3611 |
| 2020's | 2 (8.00) | 2.80 |
| Authors | Studies |
|---|---|
| Keserü, GM | 1 |
| Caron, G; Ermondi, G | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
| Jia, L; Sun, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Sen, S; Sinha, N | 1 |
| Freiwald, S; Jiang, Y; Jones, JP; Kaspera, R; Katayama, J; Lee, CA; Smith, E; Totah, RA; Walker, GS | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Ciummo, PE; Katz, NL | 1 |
| Swims, MP | 1 |
| Cook, MD; Jue, SG; Marchiando, RJ | 1 |
| Bergstrom, RF; Cerimele, BJ; Goldberg, MJ; Hatcher, BL | 1 |
| Purcell, P; Valmana, A | 1 |
| Jurima-Romet, M; Neigh, S; Wright, M | 1 |
| Furutani, K; Inanobe, A; Kurachi, Y; Ohno, Y; Yamakawa, Y | 1 |
| Cavalli, RC; Duarte, G; Lanchote, VL; Moisés, ECD; Moreira, FL; Nardotto, GHB; Pinto, L | 1 |
| Bapat, P; Berger, H; de Carvalho Cavalli, R; de Lima Moreira, F; Koren, G; Lanchote, VL; Lubetsky, A; Pinto, L | 1 |
25 other study(ies) available for terfenadine and fluoxetine
| Article | Year |
|---|---|
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
Topics: 1-Octanol; Alkanes; Hydrogen-Ion Concentration; Least-Squares Analysis; Mathematics; Models, Chemical; Models, Molecular; Solvents; Water | 2005 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
Topics: Amiodarone; Astemizole; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Danazol; Drug Discovery; Drug Interactions; Enzyme Inhibitors; Humans; Hydroxylation; In Vitro Techniques; Methylation; Microsomes, Liver; Models, Biological; Molecular Structure; Substrate Specificity; Tandem Mass Spectrometry; Terfenadine | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Interactions and drug-metabolizing enzymes.
Topics: Adolescent; Adult; Anti-Allergic Agents; Antidepressive Agents, Second-Generation; Antifungal Agents; Binding Sites; Biotransformation; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Enzyme Induction; Erythromycin; Female; Fluoxetine; Humans; Isoenzymes; Ketoconazole; Liver; Male; Middle Aged; Pharmaceutical Preparations; Terfenadine; Theophylline; Torsades de Pointes | 1995 |
Potential terfenadine-fluoxetine interaction.
Topics: Adult; Drug Interactions; Electrocardiography, Ambulatory; Fluoxetine; Humans; Male; Tachycardia, Sinus; Terfenadine | 1993 |
Probable terfenadine-fluoxetine-associated cardiac toxicity.
Topics: Adult; Anti-Allergic Agents; Antidepressive Agents, Second-Generation; Drug Interactions; Female; Fluoxetine; Heart Diseases; Humans; Terfenadine | 1995 |
Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine.
Topics: Area Under Curve; Biological Availability; Blood Pressure; Drug Interactions; Electrocardiography; Fluoxetine; Half-Life; Heart; Heart Rate; Histamine H1 Antagonists; Humans; Male; Metabolic Clearance Rate; Selective Serotonin Reuptake Inhibitors; Terfenadine | 1997 |
Fluoxetine-terfenadine and sexual dysfunction.
Topics: Anti-Allergic Agents; Drug Therapy, Combination; Fluoxetine; Humans; Male; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunction, Physiological; Terfenadine | 1998 |
Terfenadine-antidepressant interactions: an in vitro inhibition study using human liver microsomes.
Topics: Alkylation; Antidepressive Agents, Second-Generation; Biotransformation; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Fluoxetine; Histamine H1 Antagonists; Humans; Hydroxylation; Microsomes, Liver; Mixed Function Oxygenases; Piperazines; Sertraline; Terfenadine; Triazoles | 1998 |
Pharmacophore modeling for hERG channel facilitation.
Topics: Animals; Atenolol; Chlorpheniramine; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Fluoxetine; Haloperidol; Humans; Hydrophobic and Hydrophilic Interactions; Imipramine; Metoprolol; Nortriptyline; Potassium Channel Blockers; Promethazine; Propranolol; Quantitative Structure-Activity Relationship; Sotalol; Terfenadine; Verapamil; Xenopus laevis | 2012 |
Chiral Discrimination of P-glycoprotein in Parturient Women: Effect of Fluoxetine on Maternal-Fetal Fexofenadine Pharmacokinetics.
Topics: Adult; Antidepressive Agents, Second-Generation; ATP Binding Cassette Transporter, Subfamily B; Case-Control Studies; Drug Interactions; Female; Fetal Blood; Fluoxetine; Histamine H1 Antagonists, Non-Sedating; Humans; Intestinal Absorption; Intestinal Mucosa; Maternal-Fetal Exchange; Parturition; Placental Circulation; Pregnancy; Terfenadine; Young Adult | 2020 |
Chiral Transplacental Pharmacokinetics of Fexofenadine: Impact of P-Glycoprotein Inhibitor Fluoxetine Using the Human Placental Perfusion Model.
Topics: Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; Drug Interactions; Female; Fluoxetine; Histamine H1 Antagonists, Non-Sedating; Humans; Maternal-Fetal Exchange; Perfusion; Placenta; Pregnancy; Pregnancy Complications; Stereoisomerism; Terfenadine | 2021 |